VNDA

Vanda Pharmaceuticals Inc

3.79

Oct 30 • 3:59 PM ET -0.26 (-6.42%)

3.83

Aftermarket • 7:30 PM ET +0.04 (1.06%)

Healthcare Biotechnology USA Micro NASD

Oct 29, 3:23 AMVanda delivers Q3 beat with 24% revenue growth, sharp cost cuts and 2026 product sales guidance above $240M

Peers: HRMY ACAD AXSM JAZZ SUPN ALKS NERV LBRX NBIX BIIB

| Held by: VTI XBI IWM VXF IWN DFAS IBB DFSV VTWO SCHA

Scroll to Statements

Index	RUT
Market Cap	229.18M
Enterprise Value	110.66M
Income	-274.83M
Sales	229.28M
Book/sh	3.31
Cash/sh	2.32
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	533
IPO	Apr 12, 2006

P/E	-
Forward P/E	-
PEG	-
P/S	1.00
P/B	1.15
P/C	1.63
P/FCF	-
EV/EBITDA	-
EV/Sales	0.48
Quick Ratio	1.53
Current Ratio	1.54
Debt/Eq	0.11
LT Debt/Eq	0.09
Option/Short	Yes / Yes

EPS (ttm)	-4.62
EPS next Y	-0.72
EPS next Q	-0.37
EPS this Y	29.41%
EPS next Y	72.65%
EPS next 5Y	47.86%
EPS past 3/5Y	- -
Sales past 3/5Y	-5.29% -2.73%
EPS Y/Y TTM	-222.50%
Sales Y/Y TTM	8.11%
EPS Q/Q	2.38%
Sales Q/Q	24.10%
Earnings	Oct 28 AMC
EPS/Sales Surpr.	45.75% 0.89%

Insider Own	5.40%
Insider Trans	0.00%
Inst Own	86.54%
Inst Trans	1.40%
ROA	-55.89%
ROE	-82.55%
ROIC	-126.56%
Gross Margin	89.33%
Oper. Margin	-77.59%
Profit Margin	-119.87%
SMA20	-9.97%
SMA50	-20.88%
SMA200	-39.01%
Trades

Shs Outstand	60.47M
Shs Float	57.21M
Short Float	14.53%
Short Ratio	8.06
Short Interest	8.31M
52W High	9.94 -61.87%
52W Low	3.79 0.00%
Volatility	9.13% 5.63%
ATR (14)	0.25
RSI (14)	26.67
Beta	0.70
Rel Volume	1.74
Avg Volume	1.03M
Volume	1,793,443

Perf Week	-5.49%
Perf Month	-21.21%
Perf Quarter	-27.53%
Perf Half Y	-45.86%
Perf YTD	-57.03%
Perf Year	-12.27%
Perf 3Y	-12.67%
Perf 5Y	-77.86%
Perf 10Y	-74.56%
Recom	1.40
Target Price	11.50
Prev Close	4.05
Price	3.79
Change %	-6.42%

Consensus

Strong Buy

Avg. Price Target

$11.50

Implied Upside

+203.4%

Analysts9incl. previous ratings

Rating Distribution6 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 23, 2026	Initiated	OOppenheimer	Outperform	$10	+163.9%
Mar 05, 2026	Initiated	TTruist	Buy	$18	+374.9%
Nov 05, 2025	Initiated	RB. Riley Securities	Buy	$11	+190.2%
Oct 31, 2024	Initiated	HH.C. Wainwright	Buy	$18	+374.9%
Jul 11, 2024	Initiated	CCantor Fitzgerald	Overweight	$11	+190.2%
Feb 25, 2022	Downgrade	JJefferies	Buy → Hold	$24 → $12	+216.6%
May 12, 2021	Initiated	BBofA Securities	Buy	$22	+480.5%
Jan 14, 2021	Downgrade	CCitigroup	Buy → Neutral	$14	+269.4%
Oct 29, 2020	Upgrade	CCitigroup	Neutral → Buy	$14	+269.4%
Jun 09, 2020	Downgrade	CCitigroup	Buy → Neutral	$14	+269.4%
Mar 16, 2020	Downgrade	OOppenheimer	Perform → Underperform
Mar 12, 2020	Upgrade	CCitigroup	Neutral → Buy	$14	+269.4%
Nov 07, 2019	Downgrade	CCitigroup	Buy → Neutral	$19	+401.3%
Aug 01, 2019	Upgrade	CCitigroup	Neutral → Buy	$19	+401.3%
Jul 25, 2019	Downgrade	SStifel	Buy → Hold	$26 → $17	+348.5%
Dec 11, 2018	Downgrade	OOppenheimer	Outperform → Perform
Dec 04, 2018	Upgrade	CCantor Fitzgerald	Neutral → Overweight
Dec 04, 2018	Reiterated	JJefferies	Buy	$30 → $40	+955.4%
Nov 08, 2018	Resumed	JJefferies	Buy
Sep 21, 2018	Resumed	OOppenheimer	Outperform

Oct-28-26 06:37PM	Vanda Pharmaceuticals Beats On A Timing-Aided Quarter, But A Guidance Cut To The Old Floor And Slower Launches Overshadow The Print (Earnings Whispers)
04:11PM	Vanda: Q3 Earnings Snapshot (Associated Press)
04:01PM	Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results (PR Newswire)
Oct-27-26 06:50AM	Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS (tradipitant) for Prevention of GLP-1-Induced Vomiting (PR Newswire)
Oct-22-26 07:22AM	Vanda Needs A Clean Third Quarter As Fanapt Gains Battle Hetlios Erosion And Cash Burn (Earnings Whispers)
05:40PM	Loading…
Oct-21-26 05:40PM	Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026 (PR Newswire)
Oct-15-26 07:33AM	Vanda puts anxiety drugs development on ice after Phase III fail (Clinical Trials Arena)
Oct-14-26 05:54PM	Vanda Pharmaceuticals stock falls after anxiety drug trial fails (Investing.com)
05:00PM	Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program (PR Newswire)
Oct-02-26 09:06AM	Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting (PR Newswire)
Sep-30-26 01:27PM	VNDA Stock Fades After Hetlioz Sleep-Trial Win Heres Why (Stocktwits)
Sep-29-26 11:47PM	Biotech Lagged The Broader Market In September Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBIs Slump? (Stocktwits)
06:45PM	Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ(tasimelteon) in Delayed Sleep-Wake Phase Disorder (PR Newswire)
Sep-02-26 04:51PM	Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences (PR Newswire)
Aug-31-26 08:00AM	BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee (TMX Newsfile)
07:00AM	Loading…
Aug-24-26 07:00AM	Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission (PR Newswire)
Aug-22-26 03:16PM	NEREUS Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. (PR Newswire)
Aug-05-26 04:07PM	Vanda: Q2 Earnings Snapshot (Associated Press)
04:01PM	Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results (PR Newswire)
Jul-29-26 04:31PM	Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 (PR Newswire)
Jul-16-26 04:30PM	Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe (PR Newswire) -6.84%
Jul-15-26 04:30PM	NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment (PR Newswire)
Jul-10-26 04:30PM	Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit (PR Newswire)
Jul-07-26 08:22PM	VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy (Stocktwits)
May-27-26 07:00AM	Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis (PR Newswire)
May-07-26 06:44PM	Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences (PR Newswire) -14.11%
May-06-26 04:07PM	Vanda: Q1 Earnings Snapshot (Associated Press)
04:01PM	Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results (PR Newswire)
May-01-26 04:35PM	Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years (PR Newswire) +8.00%
Apr-29-26 04:30PM	Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 (PR Newswire)
07:12PM	Loading…
Apr-28-26 07:12PM	Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence (PR Newswire)
Apr-22-26 05:13PM	Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors (PR Newswire)
Apr-09-26 11:02AM	Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines (PR Newswire)
Apr-08-26 04:44PM	Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists (PR Newswire)
Mar-19-26 04:34PM	Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods (PR Newswire) -16.92%
Mar-03-26 08:01AM	Vanda Announces FDA Grants Landmark Hearing for HETLIOZ in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years (PR Newswire)
Feb-26-26 04:35PM	Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference (PR Newswire)
08:35AM	Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley (TipRanks)
Feb-25-26 10:56AM	Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug (Benzinga)
07:18AM	Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis (PR Newswire)
Feb-24-26 12:44PM	What's Going On With Vanda Pharma Stock Tuesday? (Benzinga)
06:00AM	Novo to cut GLP-1 drug prices; Palvella soars on study data (BioPharma Dive)
Feb-23-26 09:00AM	Vanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatment (Benzinga) +41.49%
05:33AM	Stock Market Today: Dow Jones, S&P 500 Futures Drop After Supreme Court Strikes Down Trump's Emergency Tariffs- Novo Nordisk, Strategy, Vanda In Focus (Benzinga)
Feb-20-26 09:22PM	Vanda Pharmaceuticals stock surges after the FDA approves its new Bipolar I drug (Investing.com) -5.57%
05:59PM	Vanda Pharmaceuticals Announces FDA Approval of BYSANTI (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation (PR Newswire)
Feb-12-26 12:02AM	Vanda Pharmaceuticals Inc (VNDA) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Rising Losses (GuruFocus.com) -17.63%
Feb-11-26 06:02PM	Vanda Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
05:15PM	Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:21PM	Vanda: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
Feb-10-26 05:10PM	Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
Feb-04-26 06:01PM	Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 (PR Newswire) -5.59%
Jan-28-26 07:35AM	Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? (Zacks)
Jan-13-26 09:55AM	Vanda (VNDA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jan-08-26 07:00AM	Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ Supplemental New Drug Application for Jet Lag Disorder (PR Newswire) -14.05%
Jan-01-26 08:25AM	Vanda Pharmaceuticals price target raised to $14 from $11 at B. Riley (TipRanks)
Dec-31-25 04:34PM	Stocks Settle Lower on Tech Weakness and Higher Bond Yields (Barchart) +25.46% -6.46%
11:12AM	These Stocks Are Moving the Most Today: Nvidia, Tesla, Hecla, Newmont, Nike, Vanda, Corcept, DJT, and More (Barrons.com)
10:57AM	Vanda Jumps 21% After FDA Approves Motion Sickness Therapy (GuruFocus.com)
10:57AM	Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval (Barrons.com)
09:57AM	Stocks Slide on Weakness in Megacap Tech Stocks (Barchart)
09:54AM	Biggest Mover Wednesday: Vanda's FDA Win Sends the Stock Flying (GuruFocus.com)
07:36AM	VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains (Zacks)
Dec-30-25 06:13PM	Vanda Pharmaceuticals Announces FDA Approval of NEREUS (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness (PR Newswire)
Dec-29-25 09:13AM	3 Biotech Stocks With Major 2026 Catalysts (Zacks)
Dec-26-25 02:56PM	Christmas Week Brings S&P 500 Records, Tech Volatility (Schaeffer's Research)
11:41AM	Vanda Pharmaceuticals Stock Rallies on FDA Filing (Schaeffer's Research)
Dec-15-25 07:00AM	Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis (PR Newswire) +6.42%
Dec-11-25 05:02PM	Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference (PR Newswire) -5.61%
Dec-04-25 04:21PM	FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness (PR Newswire)
Nov-30-25 09:53AM	Should You Invest in This Under-the-Radar Weight Loss Stock? (Motley Fool)
Nov-28-25 07:00AM	Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness (PR Newswire)
Nov-19-25 10:06AM	VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects (Zacks)
05:33AM	Alkermes escalates bidding war; US biotech risks falling behind China (BioPharma Dive)
Nov-17-25 06:37PM	Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting (PR Newswire) +21.59%
Nov-05-25 05:00PM	Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference (PR Newswire)
09:51AM	Pinterest downgraded, Tractor Supply upgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 05:20PM	Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -20.15%
04:18PM	Vanda: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results (PR Newswire)
Oct-28-25 12:02PM	Jim Cramer on Vanda Pharmaceuticals: "I'm Going to Bless That One as Your Spec" (Insider Monkey)
Oct-22-25 04:30PM	Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 (PR Newswire)
Oct-08-25 08:00AM	Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena (PR Newswire)
Oct-01-25 05:02PM	Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration (PR Newswire)
Sep-25-25 08:00AM	Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial" (PR Newswire)
Aug-28-25 05:23PM	Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences (PR Newswire)
07:00AM	Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera (PR Newswire)
Aug-18-25 07:00AM	In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder (PR Newswire)
Jul-31-25 08:40AM	Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -8.78%
07:37AM	Vanda: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results (PR Newswire)
Jul-30-25 05:15PM	Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-23-25 04:45PM	Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 (PR Newswire)
Jul-18-25 07:24AM	Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains? (Zacks)
Jun-10-25 08:00AM	Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S (PR Newswire)
May-27-25 09:00AM	Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting (PR Newswire)
May-16-25 05:30PM	Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 (PR Newswire) +5.85%
May-08-25 08:04AM	Q1 2025 Vanda Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:28AM	Vanda Pharmaceuticals Inc (VNDA) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Rising ... (GuruFocus.com)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Williams Timothy	SVP & General Counsel	Mar 02 '26	Sale	8.27	42,434	350,755	377,450	Mar 04 06:54 PM
Moran Kevin Patrick	SVP, CFO & Treasurer	Mar 02 '26	Sale	8.27	42,442	350,821	411,380	Mar 04 06:53 PM
Wijkstrom Joakim	SVP, Chief Marketing Officer	Mar 02 '26	Sale	8.27	30,800	254,590	333,469	Mar 04 06:52 PM
Polymeropoulos Mihael Hristos	President and CEO	Mar 02 '26	Sale	8.17	156,235	1,276,971	2,704,496	Mar 04 06:51 PM
Birznieks Gunther	SVP, Business Development	Mar 02 '26	Sale	8.27	42,431	350,730	494,197	Mar 04 06:51 PM
Timothy Williams	SVP & General Counsel	Mar 02 '26	Proposed Sale	8.27	42,434	350,755		Mar 02 09:43 PM
Gunther Birznieks	SVP, Business Development	Mar 02 '26	Proposed Sale	8.27	42,431	350,730		Mar 02 09:27 PM
Joakim Wijkstrom	SVP, Chief Marketing Officer	Mar 02 '26	Proposed Sale	8.27	30,800	254,589		Mar 02 09:18 PM
Mihael H. Polymeropoulos	Officer	Mar 02 '26	Proposed Sale	8.17	156,235	1,276,976		Mar 02 09:15 PM
Kevin Moran	SVP, CFO & Treasurer	Mar 02 '26	Proposed Sale	8.27	42,442	350,821		Mar 02 09:09 PM
Honore Tage	Director	Feb 23 '26	Sale	8.03	30,000	240,900	93,469	Feb 24 04:28 PM
Honore Tage	Director	Feb 23 '26	Proposed Sale	8.03	30,000	240,900		Feb 23 08:03 PM

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

FounderDr. Mihael H. Polymeropoulos M.D.

Senior VPMr. Kevin Patrick Moran

Senior VP & Chief Marketing OfficerMr. Joakim Wijkstrom

Senior Vice President of Business DevelopmentMr. Gunther Birznieks

Senior VPMr. Daniel Patrick McGuire

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VNDA

Vanda Pharmaceuticals Inc

Upgrade your Finviz experience